CurrentUnitedHealthcarePolicy CSO64KS.01

Intensity-Modulated Radiation Therapy (IMRT) (for Kansas Only)

UnitedHealthcare Community Plan medical policy CSO64KS.01 governing coverage criteria for intensity-modulated radiation therapy (IMRT) for members age 19 and older in Kansas (IMRT for persons 18 and younger is covered without further review). Defines proven/medically necessary indications, exception criteria, unproven uses, applicable procedure codes, and relevant clinical evidence and guidelines.

Policy Summary

PayerUnitedHealthcare

PolicyIntensity-Modulated Radiation Therapy (IMRT) (for Kansas Only)

Policy CodePolicy CSO64KS.01

Change TypeNew policy

Effective DateJun 1, 2025

Next Review Date

Key ActionWhen requesting IMRT for indications not listed as proven, provide documentation that at least one exception criterion is met (e.g., absence of leptomeningeal disease; plan comparison showing non-IMRT would increase clinically meaningful normal tissue toxicity per RTOG/QUANTEC; or prior irradiation requiring sculpting to avoid exceeding cumulative tolerance).

POLICY UPDATE CHANGES

New Medical Policy created.

1State-specific policy (Kansas only)

MultipleCovered Indications Listed

1Unproven Indication Listed

1Policy created

UnitedHealthcare Community Plan medical policy CSO64KS.01 applies to the state of Kansas and governs coverage for intensity-modulated radiation therapy (IMRT) for members 19 years of age and older (IMRT for persons ≤ 18 years is covered without further review). The policy lists specific proven/medically necessary indications and exception criteria and reflects a mixed coverage stance—IMRT is covered for many tumor sites and scenarios but requires case-by-case review or is considered unproven for certain uses.

Quick thresholds and policy facts

HA-WBRT fraction limitHippocampal-avoidance whole brain radiation therapy (HA-WBRT) limited to up to 10 fractions

Prognosis requirementPrognosis of 4 months or greater required for coverage consideration

Performance status for HA-WBRTECOG performance status < 2 or Karnofsky performance status (KPS) ≥ 70 required for HA-WBRT

APBI fractionation (breast)Accelerated partial breast irradiation (APBI) using IMRT: up to 5 fractions

Effective datePolicy effective date: June 1, 2025

Policy numberCSO64KS.01

Scope summaryUnitedHealthcare Community Plan medical policy for Kansas defining IMRT coverage for persons ≥19 years (IMRT for ≤18 years covered without further review), listing proven indications, exception criteria, unproven uses, and referenced procedure codes

Medical-Necessity Criteria

Proven and Medically Necessary Indications

Covered when treating the primary site for definitive therapy for the following diagnoses:

ANY of the following

Anal cancer
Breast cancer: accelerated partial breast irradiation of up to 5 fractionsup to 5 fractions
APBI fractionation (breast)
Breast cancer: when the left-sided internal mammary nodes are being treated
Central nervous system (CNS) tumors (primary or benign) including the brain, brainstem, and spinal cord
Cervical cancer
Endometrial cancer
Esophageal cancer
Head and neck cancers, including lymphoma and solitary plasmacytomas, when treatment includes pharynx, larynx (stage III or IV glottic cancer), salivary glands, oral cavity, nasal cavity, or paranasal sinuses
Non-small cell lung cancer; stage III, undergoing chemoradiation therapy
Pancreatic cancer
Prostate cancer
Compensator-based beam modulation treatment when done in combination with an IMRT indication listed above as proven
Brain metastasis
HA-WBRT: Hippocampal-avoidance whole brain radiation therapy (HA-WBRT) of up to 10 fractions; AND ECOG performance status < 2 or Karnofsky performance status (KPS) ≥ 70up to 10 fractions; ECOG < 2 or KPS ≥ 70
HA-WBRT limited to up to 10 fractions and requires performance status criteria

Exceptions / Case-by-case coverage (Medically Necessary in Selected Cases)

IMRT may be covered for conditions not listed above when at least ONE of the following is present:

Requests for IMRT for conditions not listed as proven will be evaluated on a case-by-case basis; at least ONE of the following must be met:

ONE of

Absence of leptomeningeal disease
Use of clinically appropriate radiation dose and a non-IMRT technique would increase the probability of clinically meaningful normal tissue toxicity as specified by RTOG or QUANTEC guidelines, demonstrated on a comparison of treatment plans for the IMRT and non-IMRT technique (e.g., three-dimensional conformal treatment plan)
Must demonstrate plan comparison per RTOG/QUANTEC
The same or an immediately adjacent area has been previously irradiated and the dose distribution must be sculpted to avoid exceeding the cumulative tolerance dose of nearby normal tissue

Additional Instructions / Prognosis

Operational criteria and age application

This policy applies to persons 19 years of age and older; IMRT is covered without further review for persons 18 years and younger

age-based automatic coverage for pediatric population

Prognosis of 4 months or greaterprognosis of 4 months or greater

Not Medically Necessary / Unproven

The following use is considered unproven and not medically necessary due to insufficient evidence:

IMRT used in conjunction with proton beam radiation therapy

Considered unproven and not medically necessary

Coding

Referenced CPT codes for IMRT planning and deliveryCPT

77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications.
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan.
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple.
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex.
77387	Guidance for localization of target volume for delivery of radiation treatment; includes intrafraction tracking, when performed.

Referenced HCPCS / G-codesHCPCS

G6015	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session.
G6016	Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator; convergent beam modulated fields, per treatment session.
G6017	Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (3D positional tracking; gating; 3D surface tracking), each fraction of treatment.

Referenced Proton therapy codes (for context/comparison)CPT

77520	Proton treatment delivery; simple, without compensation.
77522	Proton treatment delivery; simple, with compensation.
77523	Proton treatment delivery; intermediate.
77525	Proton treatment delivery; complex.

Provider Actions and Billing Rules

Documentation Required

Age-based coverage documentation

Document member age: IMRT for persons ≤18 years is covered without further review; for persons ≥19 years apply policy criteria and document indication.

Documentation Required

Case-by-case exception documentation

When requesting IMRT for indications not listed as proven, provide documentation that at least one exception criterion is met.

Absence of leptomeningeal disease
Plan comparison showing a non-IMRT technique would increase clinically meaningful normal tissue toxicity per RTOG or QUANTEC (demonstrated on a comparison of IMRT vs non-IMRT plans)
Previously irradiated same or immediately adjacent area requiring sculpting to avoid exceeding cumulative normal tissue tolerance

Billing Rule

Use applicable procedure codes

Report the appropriate CPT/HCPCS procedure codes for IMRT planning and delivery as referenced in the policy. Listing is provided for reference and does not guarantee reimbursement — follow federal, state, and contractual requirements.

CPT: 77301, 77338, 77385, 77386, 77387
HCPCS/G-codes: G6015, G6016, G6017
Proton codes (context/comparison): 77520, 77522, 77523, 77525

Denial Risk

Not covered combination therapy risk

Requests for IMRT used in conjunction with proton beam therapy are considered unproven and not medically necessary and may be denied.

Documentation Required

Consider hippocampal avoidance WBRT plus memantine

HA-WBRT plus memantine should be considered for patients receiving WBRT for brain metastases with no metastases in the hippocampal avoidance region and expected survival ≥ 4 months; document absence of hippocampal lesions and anticipated prognosis. HA-WBRT fractionation is limited to up to 10 fractions and requires performance status criteria.

Document absence of hippocampal lesions (no metastases within the hippocampal avoidance region)
Document anticipated prognosis (prognosis of 4 months or greater)
Reference: HA-WBRT limited to up to 10 fractions and ECOG < 2 or KPS ≥ 70

Documentation Required

Prefer IMRT where OAR sparing is required

When IMRT is chosen because sparing organs at risk (OAR) is required, document the planning rationale and the OAR dose constraints used to justify the technique.

Document clinical rationale for selecting IMRT over 3D techniques (i.e., inability of 3D techniques to meet OAR constraints)
Include specific OAR constraints and dose-volume targets used in planning
Document any image-guidance (IGRT) or motion management used to achieve constraints

Documentation Required

Reference applicable clinical criteria

Reference InterQual for primary medical/surgical criteria and ASAM for SUD services when applicable; also follow applicable federal, state, and contractual benefit requirements when determining coverage.

UnitedHealthcare uses InterQual for primary medical/surgical criteria
Use ASAM criteria for substance use disorder services
Check federal, state, and contractual requirements which may supersede policy

Documentation Required

Refer to guideline dose recommendations for prostate IMRT

When treating pelvic lymph nodes for prostate cancer, document guideline-recommended dose and planning parameters including photon energy.

Pelvic nodal dose range: 45 Gy to 52 Gy
Photon energy: at least 6 MV

Background and Evidence Summary

IMRT is an advanced, high-precision external beam radiation therapy technique that modulates beam intensity to conform dose to the tumor while sparing adjacent normal tissues; image-guided radiation therapy (IGRT) is often used with IMRT to maximize accuracy and precision during planning and delivery. The policy describes IMRT/IGRT in the context of external beam radiation therapy and highlights their purpose in improving target conformity and reducing dose to organs at risk.

This policy provides coverage rationale, lists proven and medically necessary indications across multiple cancer types, and cites randomized trials and professional society guidelines (ACR, ASTRO, NCCN, ESMO/ESTRO/ESGO) supporting IMRT for specified indications. It also sets operational criteria, exception/case-by-case review conditions, and identifies at least one unproven use (combined IMRT with proton beam therapy).

Evidence / Guideline	Summary
Randomized trials / RCTs cited	Multiple randomized and phase III trials across tumor sites summarized (examples in policy include Nutting 2011 (parotid-sparing IMRT RCT), Meattini 2020 (APBI-IMRT Florence randomized trial), Viani 2016 (prostate randomized phase III), RTOG 0529/Kachnic (anal cancer phase II with long-term outcomes), Brown 2020 (HA-WBRT phase III)
Guidelines	Multiple professional guidelines referenced (ACR, ASTRO, NCCN, ESMO/ESTRO/ESGO, ASCO-SNO-ASTRO) recommending IMRT or IMRT/VMAT/IGRT for specified indications to reduce OAR dose and toxicity
Head & Neck (Nutting 2011)	PARSPORT RCT: parotid‑sparing IMRT significantly reduced grade ≥2 xerostomia at 12 and 24 months versus conventional RT (38% vs 74% at 12 months) with improved saliva recovery and QOL
HA‑WBRT (Brown 2020)	Phase III trial: HA‑WBRT plus memantine reduced risk of cognitive failure versus WBRT plus memantine (HR 0.74); no difference in OS or intracranial PFS — supports hippocampal‑avoidance WBRT for suitable patients
NSCLC (RTOG 0617 secondary analyses)	Secondary analyses: IMRT associated with lower rates of grade ≥3 pneumonitis and lower heart doses; heart dose (e.g., heart V40/V50) associated with overall survival
Esophageal cancer (ARTDECO Hulshof 2021; Xu 2017)	ARTDECO RCT: dose escalation to 61.6 Gy did not improve local progression‑free survival versus 50.4 Gy. Systematic review/meta‑analysis: IMRT results in less irradiated lung and heart volume and higher OS than 3D‑CRT, with no clear difference in pneumonitis or esophagitis
Breast cancer (Meattini 2020, Jagsi 2018)	Florence APBI‑IMRT phase III: APBI‑IMRT (30 Gy in 5) had low 10‑yr IBTR similar to WBI, with significantly less acute and late toxicity and better cosmesis; Jagsi RCT showed IMRT+DIBH reduced cardiac and lung dosimetry when treating internal mammary nodes
Endometrial cancer (Barillot 2014; Klopp 2018; ASTRO/ACR guidance)	Phase II Barillot: postoperative IMRT acute grade ≥2 GI toxicity <30% (27.1%) and no grade 3 GI toxicity; Klopp RTOG 1203 showed pelvic IMRT reduced patient‑reported acute GI and urinary toxicity versus 4‑field RT; guidelines strongly recommend IMRT to reduce toxicity
Anal cancer (Kachnic/RTOG 0529; cohort studies)	Dose‑painted IMRT (RTOG 0529) associated with reductions in several acute grade 2+/3+ toxicities versus historical CRT; retrospective and registry studies show IMRT associated with fewer treatment breaks and improved certain outcomes versus CRT
Cervical cancer (multiple studies; ASTRO/ESGO/NCCN)	Meta‑analyses and trials show IMRT reduces acute GI and GU toxicity versus 3D/2D techniques; single‑arm and retrospective series report low rates of severe toxicity and favorable outcomes; guidelines recommend IMRT to decrease toxicity in adjuvant and definitive settings
Pancreatic cancer (Bittner 2015; ASTRO guidance)	Systematic review: IMRT associated with significantly reduced acute nausea/vomiting, diarrhea and lower late GI toxicity vs 3D‑CRT; no difference in OS/PFS; ASTRO recommends modulated techniques for localized pancreatic cancer
Prostate cancer (Viani 2016; Abu‑Gheida 2019; Alicikus 2011; Sheets 2012)	Randomized and long‑term series: IMRT associated with significantly less acute and late GU/GI toxicity versus 3D‑CRT with similar biochemical control; long‑term series show low grade 3 GU/GI rates; guidelines endorse IMRT as standard EBRT technique
Central nervous system tumors / low‑grade glioma (RCTs, ASTRO/NCCN guidance)	RCTs and RCT‑based guidelines support use of conformal/IMRT techniques to spare OARs and reduce toxicity; ASTRO strongly recommends IMRT/VMAT to reduce acute and late toxicity for certain diffuse gliomas
Head & neck broader evidence (systematic reviews, RCTs)	Systematic reviews and RCTs show IMRT reduces late xerostomia and other late morbidities versus conventional techniques without compromising locoregional control or OS; evidence strength for xerostomia is high
Clinical practice guidelines (NCCN/ACR/ASTRO/ESMO/etc.)	Guidelines consistently state IMRT (and VMAT/IGRT where appropriate) is preferred when OAR sparing cannot be achieved with 3D techniques and endorse IMRT for numerous site‑specific indications in the policy
Rationale re: combined/experimental uses	Policy notes no clinical evidence supports combining IMRT with proton beam therapy in the same plan; such combined use is considered unproven and not medically necessary
Trials showing dosimetric and patient‑reported benefits	Multiple dosimetric comparisons and patient‑reported outcome studies (e.g., Jagsi, Meattini, Klopp, Movsas/RTOG0617 QOL analyses) demonstrate improved OAR dosimetry and reduced patient‑reported acute/late toxicities with IMRT in appropriate settings
Quality/safety and operational notes	Policy cites need for IGRT with IMRT for accuracy, requirement for plan comparisons for exception requests, pediatric automatic coverage, performance status and prognosis thresholds for HA‑WBRT, and CPT/HCPCS codes for planning/delivery

OpenPayer

Intensity-Modulated Radiation Therapy (IMRT) (for Kansas Only)

Coverage Summary

Medical-Necessity Criteria

Coding

Provider Actions and Billing Rules

Background and Evidence Summary

Definitions

Revision History